Raytheon awarded $71 million in Navy contracts for missile systems
In a recent filing with the Securities and Exchange Commission, Surrozen , Inc. (NASDAQ:SRZN) disclosed significant stock purchases by The Column Group, a major shareholder. The transactions, dated March 26, 2025, reveal that The Column Group acquired a substantial number of shares in the biotechnology company, which currently has a market capitalization of $37 million. According to InvestingPro data, the stock has experienced an 11.5% decline over the past week.
The Column Group III, LP, along with its affiliates, purchased a total of 1,034,482 shares of Surrozen’s common stock at a price of $11.60 per share, amounting to an investment of approximately $11.9 million. This acquisition reflects The Column Group’s continued interest and confidence in Surrozen’s potential within the life sciences sector. InvestingPro analysis suggests the company maintains strong liquidity with a healthy current ratio of 7.4 and more cash than debt on its balance sheet.
The purchases were made by various entities under The Column Group umbrella, including The Column Group III, LP, The Column Group III-A, LP, and The Column Group Opportunity (SO:FTCE11B) III, LP. These entities are recognized as ten percent owners of Surrozen, underscoring their significant stake in the company.
Surrozen, based in South San Francisco, is involved in the development of regenerative medicines targeting specific tissues and organs. With The Column Group’s latest investment, the company may gain further momentum in advancing its research and development initiatives.
In other recent news, Surrozen Inc. has secured $175 million in funding to advance its focus on eye disease treatments. This funding will support the company’s ophthalmology pipeline through Phase 1 studies, following the discontinuation of their SZN-043 program for severe alcohol-associated hepatitis due to insufficient early clinical benefit. The private placement, led by Venrock Healthcare Capital Partners (WA:CPAP), is structured in two tranches, with the initial $70 million expected soon and the remaining $105 million contingent on FDA clearance for SZN-8141’s Investigational New Drug Application. Surrozen’s ophthalmology portfolio includes promising candidates SZN-8141 and SZN-8143, designed to treat retinopathies such as Diabetic Macular Edema and wet Age-Related Macular Degeneration.
Additionally, H.C. Wainwright has initiated coverage on Surrozen with a Buy rating and a price target of $32.00, highlighting the company’s focus on Wnt signaling for tissue regeneration. The analyst emphasized the potential of Wnt signaling in treating degenerative diseases and noted the strategic partnership with Boehringer Ingelheim for the development of SZN-413 for retinal diseases. Surrozen’s preclinical pipeline also includes candidates targeting conditions like wet age-related macular degeneration and diabetic macular edema. The recent developments reflect Surrozen’s commitment to advancing its Wnt pathway modulation technology in pursuit of innovative treatments for severe eye diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.